Viz-hcm

Intervention

1 paper2 findings

  • 1 lab in 1 country
  • Humans1

Outcomes

2

Time to SCD risk stratification

downin humans1

1 study
  1. Viz-hcm decreases time to SCD risk stratification in humans.

    “Similarly, the timeline for developing individualized SCD risk stratification profiles was significantly shortened.”

    Human trialNovember 2024 to March 25, 2025n = 48

    Improving Early Detection of Hypertrophic Cardiomyopathy Using Viz-HCM: A Quality Improvement Initiative Leveraging Artificial Intelligence-Assisted EKG HCM Screening

    AHA Scientific Sessions 2025 abstract3 Nov 2025

Time to diagnosis

downin humans1

1 study
  1. Viz-hcm decreases time to diagnosis in humans (mean of 37 days).

    “Time from EKG flag to diagnostic confirmation was reduced from years—as noted in historical literature—to a mean of 37 days.”

    Human trialNovember 2024 to March 25, 2025n = 48

    Improving Early Detection of Hypertrophic Cardiomyopathy Using Viz-HCM: A Quality Improvement Initiative Leveraging Artificial Intelligence-Assisted EKG HCM Screening

    AHA Scientific Sessions 2025 abstract3 Nov 2025

Latest

Nov 2025: 1Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months